Advanced Wastewater Remediation and Interim Financial Growth

MyCelx Technologies Corp. (LSE:MYX) delivered substantial revenue growth and commercial pipeline expansion across its proprietary water treatment operations in interim results for the six months ended 30 June 2026, released in September 2026. The clean water technology pioneer specializes in molecular-level filtration systems that remove hydrocarbons, toxic chemicals, and per- and polyfluoroalkyl substances (PFAS 'forever chemicals') from industrial wastewater and produced water.

For the first half of 2026, MyCelx reported a 26% increase in revenue to 2.11 million dollars compared to 1H 2025, with net loss narrowing by 25% to 1.43 million dollars. Commercial expansion was anchored by key produced water treatment contracts in the Middle East and North America. In a significant operational breakthrough, management announced that its commercial contract pipeline has tripled following technical qualification and vendor approval by a leading international oil major.

PFAS 'Forever Chemical' Filtration and Industrial Deployments

Operationally, MyCelx is capturing structural growth from tightening global environmental regulations concerning PFAS contamination in municipal water supplies and industrial discharges. The company's patented polymer chemistry permanently binds PFAS molecules, removing them to non-detectable parts-per-trillion levels at a fraction of the operating cost of conventional granular activated carbon or ion exchange resins. Continued field trials with industrial chemical plants and military facilities demonstrate high removal efficiency.

Financial Position, Commercialization Model and Liquidity

From a financial standpoint, MyCelx operates an agile commercial model combining equipment leasing, consumable media sales, and fixed service fees. The company recorded annual dividend distributions of zero pence per share, dedicating operational liquidity to pilot trials and media manufacturing. Working capital management remains disciplined, with proceeds from expanding produced water service contracts supporting operational cash flow.

Material Regulatory Risks and Forthcoming Milestones

Material risks facing MyCelx include lengthy commercial contract negotiation timelines with multinational energy corporations, government environmental regulation enforcement delays, and working capital requirements for manufacturing filtration media. Conversion of early-stage trials into multi-year commercial contracts is essential to achieving sustainable corporate profitability. Furthermore, competition from established water utility conglomerates requires ongoing technological validation.

Key forthcoming milestones include converting qualified pipeline bids into binding commercial contracts, expanding PFAS remediation installations across the US, and reporting full-year audited financial accounts in early 2027. MyCelx's patented molecular chemistry, regulatory tailwinds, and expanding oil major approvals provide steady momentum in the UK listed market. In summary, sustained commercial discipline across core technical operations, paired with prudent overhead controls and active balance sheet oversight, provides the operational stability required to navigate ongoing macroeconomic challenges. Executive management remains committed to protecting core customer franchises, maintaining rigorous quality benchmarks, and optimising internal resource allocation across all established trading divisions. Ongoing engagement with industrial counterparties and systematic execution of stated strategic priorities will determine the enterprise's long-term commercial trajectory as future statutory financial disclosures and scheduled operational updates are formally presented to market participants in due course. Delivering sound cost containment, stable working capital management, and consistent manufacturing execution across primary production sites will remain central to sustaining institutional confidence and driving operational progress in future trading periods. Furthermore, management continues to prioritise strategic operational resilience, selective capacity investment, and proactive client communication to ensure business continuity across changing economic cycles. Clear alignment between commercial objectives and day-to-day shopfloor execution underpins the enterprise's broader operational roadmap. Industry counterparties and institutional observers will continue tracking key execution milestones, governance standards, and cash conversion performance as scheduled corporate updates are published throughout the financial year. Continuous operational review, sound financial discipline, and responsive commercial adaptation across domestic and overseas sales channels ensure the business remains positioned to address evolving industry dynamics. By maintaining tight managerial controls, monitoring working capital velocity.